SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-23-007582
Filing Date
2023-11-02
Accepted
2023-11-02 12:18:40
Documents
13
Period of Report
2023-11-02
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sunshine_8k.htm   iXBRL 8-K 27376
  Complete submission text file 0001683168-23-007582.txt   244719

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE sbfm-20231102.xsd EX-101.SCH 3553
3 XBRL DEFINITION FILE sbfm-20231102_def.xml EX-101.DEF 26585
4 XBRL LABEL FILE sbfm-20231102_lab.xml EX-101.LAB 36550
5 XBRL PRESENTATION FILE sbfm-20231102_pre.xml EX-101.PRE 25209
7 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_8k_htm.xml XML 5126
Mailing Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5
Business Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5 514-426-6161
Sunshine Biopharma, Inc (Filer) CIK: 0001402328 (see all company filings)

IRS No.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41282 | Film No.: 231370955
SIC: 2834 Pharmaceutical Preparations